|Mapatumumab (Code C61502)|
|Terms & Properties|
Preferred Name: Mapatumumab
Definition: A fully human agonistic monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. TRAIL-R1 is a cell surface receptor expressed on many malignant cell types. Mapatumumab selectively binds to and activates the TRAIL cell receptor, thereby inducing apoptosis and reducing tumor growth.
NCI-GLOSS Definition: A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL R1 on the surface of some tumor cells. This may kill the tumor cells. Anti-TRAIL R1-mAb is a type of monoclonal antibody.
Display Name: Mapatumumab
NCI Metathesaurus Link: C1665688 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|PDQ Closed Trial Search ID||486626|
|PDQ Open Trial Search ID||486626 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
|Semantic_Type||Amino Acid, Peptide, or Protein|
Additional Concept Data:
|Defined Fully by Roles: No|